| Document Date: 2014-01-07 14:36:35
Open Document File Size: 165,75 KBShare Result on Facebook
City Lafayette / New Orleans / PLYMOUTH / / Company ProNAi Therapeutics Inc. / / / Event FDA Phase / / Facility Van Elslander Cancer Center / St. John Providence Hospital / / IndustryTerm cancer therapy / Therapies for Lymphoma / lymphoma therapies / / MedicalCondition hyperkalemia / tumor / hypocalcemia / renal failure/dysfunction / cancer / Lymphoma / tumors / disease / hyperphosphatemia / follicular lymphoma / symptomatic disease / advanced solid tumors / lymphoma therapies / diffuse large B-cell lymphoma / human tumors / tumor lysis syndrome / Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma / hematologic tumors / infections / hematological and solid tumor / / MedicalTreatment antibody therapy / cancer therapy / / Organization American Society for Hematology / Van Elslander Cancer Center in Detroit / St. John Providence Hospital / Medical Center / / Person Wael Harb / Ayad Al-Katib / Mina Sooch / / / Position CEO / leader / study investigator / principal investigator / Director / / Product DNAi drug delivery platform / DNAi / BCL2 / PNT2258 / BCL2-Inhibitor / activity / / ProvinceOrState Indiana / Louisiana / Michigan / / SportsEvent NHL / / Technology drug delivery / Chemotherapy / treating cancer / apoptosis / / URL www.pronai.com / /
SocialTag |
ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting December 09, :00 PM Eastern Standard Time ASH 2013 PLYMOUTH, Mich.--(B